高等学校化学学报 ›› 2011, Vol. 32 ›› Issue (10): 2316.

• 研究论文 • 上一篇    下一篇

1,3,4-噁二唑键联二芳基乙烯化合物的合成及性质

翟树荣, 朱雪峰, 曾和平   

  1. 华南理工大学化学与化工学院功能分子研究所, 广州 510641
  • 收稿日期:2010-11-11 出版日期:2011-10-10 发布日期:2011-10-10
  • 通讯作者: 曾和平 E-mail:hpzeng@scut.edu.cn
  • 基金资助:

    国家自然科学基金项目(批准号:  21071054)和广东省科技计划项目(批准号:  2008B010800030, 2009B091300045和2010B090400495)资助.

Synthesis and Properties of Two Photochromic Diarylethenes Containing 1,3,4-Oxadiazoles

ZHAI Shu-Rong, ZHU Xue-Feng, ZENG He-Ping*   

  1. Institute of Functional Molecules, School of Chemistry and Chemical Engineering, South China University of Technology, Guangzhou 510641, China
  • Received:2010-11-11 Online:2011-10-10 Published:2011-10-10
  • Contact: ZENG He-Ping E-mail:hpzeng@scut.edu.cn
  • Supported by:

    国家自然科学基金项目(批准号:  21071054)和广东省科技计划项目(批准号:  2008B010800030, 2009B091300045和2010B090400495)资助.

摘要: 将1,3,4-噁二唑基团引入二芳基乙烯分子中, 合成了2种新的二芳基乙烯类光致变色化合物1-氰基-2-(2H-5-苯基-1,3,4-噁二唑)-1,2-二(2,4,5-三甲基-3-噻吩)乙烯(3)和1,4-二{[1-氰基-2-(2H-5-苯基-1,3,4-噁二唑)-1,2-二(2,4,5-三甲基-3-噻吩)乙烯]-1,3,4-噁二唑}苯(4).  通过IR, NMR, MS和元素分析对化合物进行了结构表征, 并研究了其UV-Vis吸收、荧光发射、动力学特性和抗疲劳性质. 实验结果表明, 化合物[STHZ]3[STBZ]和[STHZ]4[STBZ]具有良好的光致变色性质, 光致变色闭环反应为零级反应, 开环反应为一级反应.

关键词: 二芳基乙烯, 光致变色, 光谱特性

Abstract: Two novel photochromic dithienylethenes compounds, (E)-3-(5-phenyl-1,3,4-oxadiazol-2-yl)-2,3-bis(2,4,5-trimethylthiophen-3-yl)acrylonitrile(3) and (Z)-3-[5-(4-{5-[(E)-2-cyano-1,2-bis(2,4,5-trimethylthiophen-3-yl)vinyl]-1,3,4-oxadiazol-2-yl}phenyl)-1,3,4-oxadiazol-2-yl]-2,3-bis(2,4,5-trimethylthiophen-3-yl)acrylonitrile(4) containing 1,3,4-oxadiazoles, were synthesized. Their structures were confirmed by IR, NMR, MS and elemental analysis.  Moreover, their UV-Vis absorption properties, fluorescent properties, photochromic dynamics character and fatigue resistance were studied.  The results indicated that they processed good photochromic behavior, and their cyclization and cycloreversion reactions were zeroth and first order reaction, respectively.

Key words: Dithienylethene, Photochromic, Optoelectronic property

TrendMD: